Literature DB >> 23150437

p53 Ubiquitination and proteasomal degradation.

Ian M Love1, Dingding Shi, Steven R Grossman.   

Abstract

p53 levels and activity are controlled in large part through regulated ubiquitination and subsequent destruction by the 26S proteasome. Monoubiquitination of p53 is mediated primarily by the RING-finger E3 ubiquitin ligase MDM2 and impacts p53 activity through modulation of p53 localization and transcription activities. Recently, several E4 ubiquitin ligases (E4s) have been identified which serve to extend these monoubiquitin chains. The ubiquitin ligase activity of these factors toward p53, and their contribution to p53 degradation, can be studied using a variety of in vitro and in vivo methods and reagents which will be described in this chapter. These methods include in vivo ubiquitination of p53 using HA-ubiquitin or his-ubiquitin; the in vitro E3 ubiquitin ligase assay, in which ubiquitin reaction components (URC) are incubated with a purified E3 or E4 ligase; a one-step E4 assay, in which URC are incubated with a substrate, E3, and E4; and a two-step E4 assay in which p53 is monoubiquitinated in an E3 reaction, and subsequently purified and incubated with an E4. Finally, we will describe an in vitro degradation assay in which ubiquitinated p53 is incubated with purified 26S proteasomes. Together, these assays can be used to provide insight into the biochemical nature of p53 ubiquitination and degradation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23150437     DOI: 10.1007/978-1-62703-236-0_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

Review 1.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

2.  Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.

Authors:  Aslamuzzaman Kazi; Sevil Ozcan; Awet Tecleab; Ying Sun; Harshani R Lawrence; Saïd M Sebti
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

3.  Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24.

Authors:  Geeta Rao; Hailey Houson; Gregory Nkepang; Hooman Yari; Chengwen Teng; Vibhudutta Awasthi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-10       Impact factor: 4.052

4.  Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic.

Authors:  Sonal Sawhney; Kylie Hood; Alisha Shaw; Antony W Braithwaite; Richard Stubbs; Noelyn A Hung; Janice A Royds; Tania L Slatter
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

5.  Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth.

Authors:  Z-J Ren; X-Y Nong; Y-R Lv; H-H Sun; P-P An; F Wang; X Li; M Liu; H Tang
Journal:  Cell Death Dis       Date:  2014-08-21       Impact factor: 8.469

6.  Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.

Authors:  Frederick M Tomlin; Ulla I M Gerling-Driessen; Yi-Chang Liu; Ryan A Flynn; Janakiram R Vangala; Christian S Lentz; Sandra Clauder-Muenster; Petra Jakob; William F Mueller; Diana Ordoñez-Rueda; Malte Paulsen; Naoko Matsui; Deirdre Foley; Agnes Rafalko; Tadashi Suzuki; Matthew Bogyo; Lars M Steinmetz; Senthil K Radhakrishnan; Carolyn R Bertozzi
Journal:  ACS Cent Sci       Date:  2017-10-25       Impact factor: 14.553

7.  Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.

Authors:  Mopei Wang; Li Liang; Jiaxiong Lu; Yang Yu; Yanling Zhao; Zhenfeng Shi; Hui Li; Xin Xu; Yuxian Yan; Yan Niu; Zhentao Liu; Lin Shen; Hong Zhang
Journal:  Thorac Cancer       Date:  2019-03-18       Impact factor: 3.500

Review 8.  Cellular Signal Transductions and Their Inhibitors Derived from Deep-Sea Organisms.

Authors:  Liyan Wang; Kazuo Umezawa
Journal:  Mar Drugs       Date:  2021-04-05       Impact factor: 5.118

Review 9.  Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer.

Authors:  Priyanka Banerjee; Sivareddy Kotla; Loka Reddy Velatooru; Rei J Abe; Elizabeth A Davis; John P Cooke; Keri Schadler; Anita Deswal; Joerg Herrmann; Steven H Lin; Jun-Ichi Abe; Nhat-Tu Le
Journal:  Front Cardiovasc Med       Date:  2021-10-20

10.  Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome.

Authors:  Geeta Rao; Gregory Nkepang; Jian Xu; Hooman Yari; Hailey Houson; Chengwen Teng; Vibhudutta Awasthi
Journal:  Front Chem       Date:  2018-09-10       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.